Considering that the GnRH antagonist protocol is widely used in PCOS patients due to its significant advantages over the agonist protocol (48–50), we believe that PPOS can achieve similar clinical outcomes as the GnRH antagonist protocol in patients with PCOS. This evidence concerns the gene GNRH1 and polycystic ovary syndrome.